_
Alzheimer's cure: World General Media News Headlines
Alzheimer's treatment: World General Media News Headlines
Alzheimer theories: World General Media News Headlines
Alzheimer science professional news: Alzforum News & Views
December 15, 2005
Eisai Sues Teva over Alzheimer's Disease Drug
"TOKYO (8 Dec 2005) - Eisai Co. Ltd. (4523.T: Quote, Profile, Research), Japan's fourth-largest drug maker, said on Thursday it was suing Teva Pharmaceutical Industries Ltd. (TEVA.O: Quote, Profile, Research) over the Israeli firm's plans to launch a copycat version of its top-selling Alzheimer's disease drug Aricept.
Eisai filed the patent infringement lawsuit against the generic drug maker in the U.S. District Court for the District of New Jersey. The Japanese drug maker received a notice from Teva in late October that it had applied to U.S. regulators to market a generic version of Aricept, an Eisai spokeswoman said. Teva was not available for comment.
Sales of Aricept, which is marketed in 76 countries worldwide, totalled 162.9 billion yen ($1.35 billion) for the year ended March 2005 and is projected to rise to 188 billion yen this year. "Eisai believes that its ... patent is valid until its expiration date of Nov. 25, 2010. Eisai intends to vigorously enforce and defend that patent," the company said in a news release.
Shares in Eisai were up 0.2 percent at 4,980 yen at the midday break, in line with the pharmaceutical sector index (.IPHAM.T: Quote, Profile, Research). ($1=121.08 Yen)
Source: Eisai sues Teva over Alzheimer's disease drug. Reuters. (8 December 2005) [FullText]
Eisai filed the patent infringement lawsuit against the generic drug maker in the U.S. District Court for the District of New Jersey. The Japanese drug maker received a notice from Teva in late October that it had applied to U.S. regulators to market a generic version of Aricept, an Eisai spokeswoman said. Teva was not available for comment.
Sales of Aricept, which is marketed in 76 countries worldwide, totalled 162.9 billion yen ($1.35 billion) for the year ended March 2005 and is projected to rise to 188 billion yen this year. "Eisai believes that its ... patent is valid until its expiration date of Nov. 25, 2010. Eisai intends to vigorously enforce and defend that patent," the company said in a news release.
Shares in Eisai were up 0.2 percent at 4,980 yen at the midday break, in line with the pharmaceutical sector index (.IPHAM.T: Quote, Profile, Research). ($1=121.08 Yen)
Source: Eisai sues Teva over Alzheimer's disease drug. Reuters. (8 December 2005) [FullText]
posted by Dr. Koudinov @ 15.12.05
Latest PubMed 20 review articles on Alzheimer’s
Latest PubMed 20 research articles on Alzheimer’s amyloid
Latest PubMed 50 research titles on Alzheimer’s
0 Comments:
Post a Comment
<< Home